Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding

Yuan,Shu‑Qiang; Nie,Run‑Cong; Chen,Yong‑Ming; Qiu,Hai‑Bo; Li,Xiao‑Ping; Chen,Xiao‑Jiang; Xu,Li‑Pu; Yang,Li‑Fang; Sun,Xiao‑Wei; Li,Yuan‑Fang; Zhou,Zhi‑Wei; Chen,Shi; Chen,Ying‑Bo

doi:10.3892/ol.2018.7826

Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding

Authors:
- Shu‑Qiang Yuan
- Run‑Cong Nie
- Yong‑Ming Chen
- Hai‑Bo Qiu
- Xiao‑Ping Li
- Xiao‑Jiang Chen
- Li‑Pu Xu
- Li‑Fang Yang
- Xiao‑Wei Sun
- Yuan‑Fang Li
- Zhi‑Wei Zhou
- Shi Chen
- Ying‑Bo Chen
View Affiliations

Affiliations: Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Department of General Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat‑sen University, Jiangmen, Guangdong 529030, P.R. China, Department of Gastric Surgery, The 6th Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China
Published online on: January 19, 2018 https://doi.org/10.3892/ol.2018.7826
Pages: 4193-4200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Glasgow Prognostic Score (GPS) has been shown to be associated with survival rates in patients with advanced cancer. The present study aimed to compare the GPS with the Eastern Cooperative Oncology Group Performance Status (ECOG PS) in patients with gastric cancer with peritoneal seeding. For the investigation, a total of 384 gastric patients with peritoneal metastasis were retrospectively analyzed. Patients with elevated C‑reactive protein (CRP; >10 mg/l) and hypoalbuminemia (<35 mg/l) were assigned a score of 2. Patients were assigned a score of 1 if presenting with only one of these abnormalities, and a score of 0 if neither of these abnormalities were present. The clinicopathologic characteristics and clinical outcomes of patients with peritoneal seeding were analyzed. The results showed that the median overall survival (OS) of patients in the GPS 0 group was longer, compared with that in the GPS 1 and GPS 2 groups (15.50, vs. 10.07 and 7.97 months, respectively; P<0.001). No significant difference was found between the median OS of patients with a good performance status (ECOG <2) and those with a poor (ECOG ≥2) performance status (13.67, vs. 11.80 months; P=0.076). In the subgroup analysis, the median OS in the GPS 0 group was significantly longer, compared with that in the GPS 1 and GPS 2 groups, for the patients receiving palliative chemotherapy and patients without palliative chemotherapy. Multivariate survival analysis demonstrated that CA19‑9, palliative gastrectomy, first‑line chemotherapy and GPS were the prognostic factors predicting OS. In conclusion, the GPS was superior to the subjective assessment of ECOG PS as a prognostic factor in predicting the outcome of gastric cancer with peritoneal seeding.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chen S, Li YF, Feng XY, Zhou ZW, Yuan XH and Chen YB: Significance of palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol. 106:862–871. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G and Miwa K: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 178:256–262. 1999. View Article : Google Scholar : PubMed/NCBI
5	Sachlova M, Majek O and Tucek S: Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer. Nutr Cancer. 66:1362–1370. 2014. View Article : Google Scholar : PubMed/NCBI
6	Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y and Sakai S: Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer. 85:1634–1639. 2001. View Article : Google Scholar : PubMed/NCBI
7	Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y and Sugimachi K: Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor marker. Cancer Lett. 192:89–95. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K and Takenaka K: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 103:1856–1864. 2005. View Article : Google Scholar : PubMed/NCBI
9	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI
10	Crumley AB, McMillan DC, McKernan M, McDonald AC and Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 94:637–641. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ishizuka M, Nagata H, Takagi K, Horie T and Kubota K: Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 246:1047–1051. 2007. View Article : Google Scholar : PubMed/NCBI
12	Crumley AB, Stuart RC, McKernan M, McDonald AC and McMillan DC: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 23:e325–e329. 2008. View Article : Google Scholar : PubMed/NCBI
13	Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 100:701–706. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H and Tajiri H: Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 107:988–993. 2012. View Article : Google Scholar : PubMed/NCBI
15	Roxburgh CS and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6:149–163. 2010. View Article : Google Scholar : PubMed/NCBI
16	Gao Y and Huang D: The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: A literature review. J Cancer Res Ther. 10:799–804. 2014. View Article : Google Scholar : PubMed/NCBI
17	Japanese Research Society for Gastric Cancer, . Japanese Classification of Gastric Carcinoma. 1st English. Tokyo: Kanehara & Co, Ltd; 1995
18	Andreyev HJ, Norman AR, Oates J and Cunningham D: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 34:503–509. 1998. View Article : Google Scholar : PubMed/NCBI
19	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
20	Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH and Chung IJ: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 11:4892011. View Article : Google Scholar : PubMed/NCBI
21	Du Clos TW: Function of C-reactive protein. Ann Med. 32:274–278. 2000. View Article : Google Scholar : PubMed/NCBI
22	Du Clos TW and Mold C: C-reactive protein: An activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 30:261–277. 2004. View Article : Google Scholar : PubMed/NCBI
23	Slaviero KA, Clarke SJ and Rivory LP: Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 4:224–232. 2003. View Article : Google Scholar : PubMed/NCBI
24	McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J and McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 41:64–69. 2001. View Article : Google Scholar : PubMed/NCBI
25	Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et al: Evaluation of modified glasgow prognostic score for pancreatic cancer: A retrospective cohort study. Pancreas. 45:211–217. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS, Huang MH and Huang BS: Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg. 8:1041–1048. 2004. View Article : Google Scholar : PubMed/NCBI
27	Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, et al: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 18:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
28	Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
29	Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP and Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI